Young people avoiding the news, Reuters report

An alarming number of young people are turning away from the news, according to the Reuters Digital News Report presented at ...
The Caledonian-Record

AL-S Pharma Presents AP-101 Phase 2 Data Supporting Misfolded SOD1 as a Therapeutic Target in ALS at ENCALS 2026

AP-101 is an investigational human-derived antibody that selectively targets the misfolded, toxic form of superoxide dismutase 1 (SOD1) to disrupt the progressive spread of ALS. The goal of this ...

Developing AI Foundations: The Architecture of Smart Systems

A good software architecture ensures that an AI system does not depend on the performance of a specific model.
The Joplin Globe

Marea Therapeutics Presents Phase 1 Data Supporting Potential Best-in-Disease Profile of MAR002 for the Treatment of Acromegaly at ENDO 2026

Marea Therapeutics, Inc., a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation medicines for cardioendocrine diseases, ...
The Caledonian-Record

ENDO 2026 Oral Presentation Highlights Comparative Clinical Data for Entera’s Breakthrough ...

The pharmacokinetic (PK) and pharmacodynamic (PD) profiles of single tablet EB613, multi-tablet EB613 and Forteo® reported for the first time as an oral presentation at ENDO 2026 ...
Eagle-Tribune

Oban BioPharma Announces Presentation of Late-Breaking Abstract at ADA 2026 Highlighting ...

STAMFORD, Conn., June 05, 2026 (GLOBE NEWSWIRE) -- Oban BioPharma today announced that preclinical data for OBT-676, a lead small-molecule candidate for the treatment of obesity and type 2 diabetes, ...